Cellectar Biosciences, Inc.: BALYASNY ASSET MANAGEMENT L.P. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Balyasny Asset Management L.P. amended its Schedule 13G stake filing for Cellectar Biosciences, Inc., according to SEC accession 0001172661-26-005040. The filing updates the asset manager's reported ownership position in the clinical-stage oncology company, though the amended document did not disclose a revised share count or percentage in the headline. The change matters because 13G amendments signal shifts in passive or institutional ownership that can influence liquidity and shareholder composition in a small-cap biotech. Investors will watch for the full filing details to confirm Balyasny's current stake and any subsequent 13D or 13G activity from other institutional holders.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Cellectar Biosciences, Inc., Balyasny Asset Management L.P.